# Parkinsons Disease Therapeutics Market

> Parkinson’s Disease Therapeutics Market Research Report Information By Treatment Type (Medication, Surgical Therapy, Carbidopa/Levodopa Enteral Suspension), By End-User (Hospitals & Clinics, Academic & Industrial Research), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.8%
- **2024:** $ 6.37 Billion
- **2025:** $ 6.93 Billion
- **2035:** $ 16.11 Billion
- **Key Players:** AbbVie (US), Boehringer Ingelheim (DE), Novartis (CH), Roche (CH), Teva Pharmaceutical Industries (IL), Amgen (US), Eli Lilly and Company (US), Sanofi (FR), Pfizer (US)

**Report ID:** MRFR/Pharma/1043-HCR · **Pages:** 90 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/parkinsons-disease-therapeutics-market-1572

---

## Market Summary

## **Global Parkinson’s Disease Therapeutics Market Overview**

Parkinson’s Disease Therapeutics Market Size was valued at USD 5.91 Billion in 2023. The Global Parkinson’s Disease Therapeutics industry is projected to grow from USD 6.37 Billion in 2024 to USD 11.61 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.80% during the forecast period (2024 - 2032).

Rising drugs approvals for treatment of Parkinson’s disease, and growing aging population and the associated increase in the prevalence of Parkinson’s disease are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Parkinson’s Disease Therapeutics Market Trends**

The aging population has been identified as a significant factor driving the market growth of Parkinson's Disease Therapeutics. Parkinson's Disease is a chronic and progressive neurological disorder that primarily affects older adults. As the global population ages, the prevalence of Parkinson's Disease is expected to increase, leading to a higher demand for therapeutics to manage the symptoms of the disease. Parkinson's Disease is more common among older adults, with the incidence of the disease increasing with age.

As the population ages, the number of people diagnosed with Parkinson's Disease is expected to rise, leading to a higher demand for therapeutic options. There are currently 10 million Parkinson's patients living in the world. Elderly adults who have the condition face key clinical symptoms include slowness, stiffness, limb tremor, and postural instability among others as the disease advances. As a result, Parkinson's disease treatment concentrates on preserving the patient's level of activity and improving quality of life.

Due to these characteristics, there is a significant need for treatments that are effective, which will drive up market revenue overall in the following years.

Additionally, UN research estimates that 727 million people worldwide would be 65 years of age or older in 2020. In addition, it is anticipated that by 2050, there will be twice as many individuals worldwide who are 80 years of age or older. Because of this, major pharmaceutical companies have been able to significantly expand their market share in this industry. For pharmaceutical companies, the availability of various dosage forms can enable product diversification, resulting in higher profitability.

According to the Parkinson’s Foundation more than 10 million people globally suffer from Parkinson Disease (PD), and 60,000 Americans have a diagnosis from Parkinson disease every year.

Increasing drug approvals for the treatment of Parkinson's disease are anticipated to stimulate market expansion during the anticipated time frame. For instance, the Japanese pharmaceutical and biotechnology company Kyowa Kirin Co., Ltd. reported in August 2019 that the NOURIANZ medication has received FDA approval in the United States (istradefylline). It is used as an additional therapy to levodopa/carbidopa in adult patients with Parkinson's disease who are having 'OFF' episodes (PD).

When a patient's medications are not functioning effectively, it can lead to an increase in Parkinson's disease (PD) symptoms like tremor and walking difficulties, which is known as a "off episode." In the US, NOURIANZ (istradefylline), an antagonist of the adenosine A2A receptor, is prescribed for Parkinson's disease. The medication offers patients with Parkinson's disease a brand-new non-dopaminergic once-daily oral therapeutic alternative.

## **Parkinson’s Disease Therapeutics Market Segment Insights**

### **Parkinson’s Disease Therapeutics Treatment Type Insights**

The Parkinson’s Disease Therapeutics Market segmentation, based on treatment Type, includes Medication, Surgical Therapy, and Carbidopa/Levodopa Enteral Suspension. The medication segment held the majority share in 2022 contribution to around ~65-67% in respect to the Parkinson’s Disease Therapeutics Market revenue. This is primarily owing to the rising prevalence of parkinson’s disease, rising research and development for the parkinson’s disease drug development that anticipated to support the market growth during forecast period.

**In November 2019,** Biogen announced the initiation of a Phase 2 clinical trial of its experimental drug BIIB094, which is being developed as a treatment for Parkinson's Disease and other neurological disorders.

**In February 2020, **Neurocrine Biosciences announced positive results from a Phase 2 clinical trial of its experimental drug NBI-827104, which is being developed as a treatment for Parkinson's Disease.

### **Parkinson’s Disease Therapeutics End-User Insights**

The Parkinson’s Disease Therapeutics Market segmentation, based on end-user, includes Hospitals & Clinics, Academic & Industrial Research. The Hospitals & Clinics segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is due to the rising prevalence of Parkinson's disease, the need for comprehensive care, advancements in treatment options, complex disease management, and access to specialized care is anticipated to support the market growth. Hence, rising demand in hospitals & clinics implants for parkinson’s disease therapeutics positively impacts the market growth.

**In May 2020,**The Cleveland Clinic announced the launch of a new telemedicine program for Parkinson's Disease patients. The program enables patients to access remote consultations with Parkinson's Disease specialists, regardless of their location.

**In February 2021,**The Penn Medicine Neuroscience Center in Philadelphia announced plans to launch a new Parkinson's Disease center, which will offer a range of clinical services and research programs.

**Figure 1: Parkinson’s Disease Therapeutics Market, by End User, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Parkinson’s Disease Therapeutics Regional Insights**

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Parkinson’s Disease Therapeutics market accounted for USD 1.95 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. With a maximum sales share of 35%-39% in 2021, North America dominated the sector globally. Its dominance can be attributable to the presence of top competitors in the area, including Sunovion Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Merck & Co. Inc., and AbbVie Inc. By launching novel PD symptom treatment products, these players promote growth.

For instance, Sunovion Pharmaceuticals Inc.'s Kynmobi was approved by the U.S. FDA in May 2020 to treat off-episodes in PD patients. Furthermore, it is projected that the region's extensive PD research will positively influence market expansion.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: PARKINSON’S DISEASE THERAPEUTICS MARKET SHARE BY REGION 2022 (%)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe parkinson’s disease therapeutics market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an ageing population, and an increase in prevenances of parkinson’s disease. Further, the Germany parkinson’s disease therapeutics market held the largest market share, and the UK parkinson’s disease therapeutics market was the fastest growing market in the European region

The Asia-Pacific Parkinson’s Disease Therapeutics Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to rising number of generic medicine makers and the world's ageing population and rising investment in healthcare sector is anticipated to support the market’s growth is the region. Moreover, China parkinson’s disease therapeutics market held the largest market share, and the India parkinson’s disease therapeutics market was the fastest growing market in the Asia-Pacific region

**Parkinson’s Disease Therapeutics Key Market Players & Competitive Insights**

Major market players are spending a lot of money on R&D to increase their product lines, which will help the parkinson’s disease therapeutics market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the parkinson’s disease therapeutics industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global parkinson’s disease therapeutics industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, parkinson’s disease therapeutics industry has provided medicine and therapy with some of the most significant benefits. The parkinson’s disease therapeutics market major player such as GlaxoSmithKline Plc, Novartis AG, Orion Corporation and others are working to expand the market demand by investing in research and development activities.

GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in London, UK. It was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. GSK is one of the largest pharmaceutical companies in the world, with operations in over 150 countries. GSK's main focus areas are pharmaceuticals, vaccines, and consumer healthcare. The company produces a range of prescription medicines, including treatments for respiratory diseases, cancer, and infectious diseases. GSK is also a leading producer of vaccines, with products targeting diseases such as influenza, meningitis, and shingles.

In addition, the company produces consumer healthcare products, such as over-the-counter medicines, oral care products, and nutritional supplements. In May 2019, GSK announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to support the development of new therapeutic strategies for Parkinson's Disease.

Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. It was founded in 1996 through a merger of Ciba-Geigy and Sandoz, two large pharmaceutical companies with a long history of drug development and innovation. Novartis is one of the largest pharmaceutical companies in the world, with operations in more than 150 countries. The company has a diverse portfolio of products, including prescription medicines, generics, biosimilars, and over-the-counter products. Novartis' main focus areas include cardiovascular and metabolic diseases, oncology, neuroscience, and ophthalmology.

In August 2019, Novartis AG announced positive results from a Phase 2 clinical trial of its experimental drug, ABBV-951. The drug is being developed in collaboration with AbbVie and is a treatment for advanced Parkinson's Disease.

**Key Companies in the parkinson’s disease therapeutics market includes**

**Parkinson’s Disease Therapeutics Industry Developments**

**In June 2019,** Biogen Inc. announced plans to acquire Nightstar Therapeutics, a gene therapy company focused on the development of treatments for inherited retinal diseases. Biogen's acquisition of Nightstar also included its Parkinson's Disease [gene therapy](../../../reports/gene-therapy-market-8399) program, which is in preclinical development.

**In October 2019, **Adamas Pharmaceuticals launched a new product, Gocovri, for the treatment of dyskinesia in Parkinson's Disease patients who are on levodopa-based therapy. Gocovri is the first and only FDA-approved medication for this indication.

**In February 2020, **Neurocrine Biosciences announced positive results from a phase 2 [clinical trial](../../../reports/clinical-trial-management-system-market-2054) of its Parkinson's Disease drug, NBI-827104. The drug showed significant improvement in motor function in patients with Parkinson's Disease, and the company plans to move forward with phase 3 trials.

## **Parkinson’s Disease Therapeutics Market Segmentation**

### **Parkinson’s Disease Therapeutics Treatment Type Outlook**

### **Parkinson’s Disease Therapeutics End-User Outlook**

### **Parkinson’s Disease Therapeutics Regional Outlook**

## Market Drivers

### Growing Awareness and Advocacy

Growing awareness and advocacy for Parkinson's Disease are contributing to the expansion of the Parkinsons Disease Therapeutics Market. Increased public knowledge about the disease, its symptoms, and its impact on patients and families is fostering a supportive environment for research and treatment initiatives. Advocacy groups are playing a crucial role in raising awareness, organizing events, and promoting fundraising efforts to support research. This heightened awareness is leading to greater demand for effective therapeutics, as patients and caregivers seek better management options. Additionally, as more individuals become informed about the disease, there is a corresponding increase in the willingness to participate in clinical trials, which is essential for the development of new therapies. Consequently, the advocacy efforts are not only enhancing the visibility of Parkinsons Disease but also driving growth in the therapeutics market.

### Rising Prevalence of Parkinson's Disease

The increasing prevalence of Parkinson's Disease is a primary driver for the Parkinson's Disease Therapeutics Market. As the population ages, the incidence of this neurodegenerative disorder is expected to rise significantly. According to recent estimates, the number of individuals diagnosed with Parkinson's Disease is projected to reach over 10 million by 2030. This growing patient population necessitates the development and availability of effective therapeutics, thereby propelling market growth. Pharmaceutical companies are investing heavily in research and development to create innovative treatment options that address both motor and non-motor symptoms. The rising prevalence not only highlights the urgent need for effective therapies but also encourages healthcare systems to allocate more resources towards managing this condition, further stimulating the Parkinson's Disease Therapeutics Market.

### Increased Research Funding and Investment

Increased research funding and investment in Parkinson's Disease therapeutics are driving the market forward. Governments and private organizations are recognizing the need for more effective treatments and are allocating substantial resources to research initiatives. In recent years, funding for Parkinsons Disease research has seen a notable increase, with millions of dollars directed towards clinical trials and innovative therapeutic approaches. This influx of capital is fostering collaboration between academic institutions and pharmaceutical companies, leading to the development of novel therapies. As a result, the Parkinsons Disease Therapeutics Market is experiencing a surge in new product pipelines, which may lead to breakthroughs in treatment options. The commitment to advancing research not only enhances the understanding of the disease but also accelerates the introduction of new therapeutics into the market.

### Regulatory Support for Innovative Therapies

Regulatory support for innovative therapies is a key driver in the Parkinson's Disease Therapeutics Market. Regulatory agencies are increasingly recognizing the need for expedited approval processes for novel treatments that address unmet medical needs. Initiatives such as breakthrough therapy designations and fast-track approvals are encouraging pharmaceutical companies to invest in the development of new therapeutics. This supportive regulatory environment is particularly important for conditions like Parkinsons Disease, where traditional treatment options may be limited. By facilitating quicker access to innovative therapies, regulatory bodies are not only enhancing patient care but also stimulating market growth. As more companies navigate the regulatory landscape successfully, the Parkinsons Disease Therapeutics Market is likely to witness an influx of new and effective treatment options, ultimately benefiting patients.

### Technological Advancements in Treatment Modalities

Technological advancements in treatment modalities are significantly influencing the Parkinson's Disease Therapeutics Market. Innovations such as deep brain stimulation and advanced drug delivery systems are enhancing the efficacy of existing therapies. For instance, the integration of wearable technology and mobile health applications is enabling real-time monitoring of patient symptoms, which can lead to more personalized treatment approaches. Furthermore, the development of gene therapy and stem cell research holds promise for potentially curative treatments. These advancements not only improve patient outcomes but also attract investment from pharmaceutical companies eager to capitalize on cutting-edge technologies. As these technologies continue to evolve, they are likely to reshape the landscape of the Parkinsons Disease Therapeutics Market, offering new hope for patients and healthcare providers alike.

## Future Outlook

The Parkinson’s Disease Therapeutics Market is projected to grow at an 8.8% CAGR from 2024 to 2035, driven by advancements in drug development, increasing patient awareness, and enhanced healthcare access.

**New opportunities:**

- Development of personalized medicine approaches for tailored treatment plans.
- Expansion of telehealth services for remote patient monitoring and consultations.
- Investment in AI-driven drug discovery platforms to accelerate therapeutic innovation.

By 2035, the market is expected to achieve substantial growth, reflecting evolving therapeutic strategies and increased patient engagement.

## Segment Insights

### By Treatment Type: Medication (Largest) vs. Surgical Therapy (Fastest-Growing)

In the Parkinson’s Disease Therapeutics Market, the distribution of market share among the various treatment types reveals that Medication holds the largest share, significantly overshadowing other segments. This category includes dopaminergic drugs such as Carbidopa/Levodopa, which are foundational in managing the symptoms of Parkinson's disease. Surgical Therapy, although smaller in market share, is recognized as the fastest-growing segment due to increasing awareness and advancements in minimally invasive techniques.

Medication (Dominant) vs. Surgical Therapy (Emerging)

Medication remains the dominant treatment type for Parkinson's Disease, primarily due to the established efficacy of conventional drug therapies. These medications are widely prescribed to alleviate symptoms and improve patients' quality of life. On the other hand, Surgical Therapy is emerging as a compelling alternative, particularly in advanced cases where medication fails to provide adequate relief. This segment benefits from innovative procedures such as Deep Brain Stimulation, which have shown promising results in enhancing motor functions. As more patients and healthcare providers explore comprehensive treatment options, the Surgical Therapy segment is anticipated to continue its upward trajectory.

### By End-User: Hospitals & Clinics (Largest) vs. Academic & Industrial Research (Fastest-Growing)

In the Parkinson’s Disease Therapeutics Market, Hospitals and Clinics represent the largest end-user segment, capturing a significant portion of market activity. These facilities are equipped with the necessary infrastructure to provide comprehensive care to Parkinson's patients, from diagnosis to ongoing treatment. In contrast, the Academic and Industrial Research segment, while smaller, is rapidly gaining traction as it plays a pivotal role in advancing therapeutic innovations and understanding the disease mechanisms.

End-User: Hospitals & Clinics (Dominant) vs. Academic & Industrial Research (Emerging)

Hospitals and Clinics dominate the Parkinson’s Disease therapeutics landscape, characterized by their extensive patient networks and access to advanced treatment protocols. These institutions often utilize a multi-disciplinary approach to manage the disease, involving neurologists, therapists, and support staff, thus enhancing patient outcomes. On the other hand, the Academic and Industrial Research segment is emerging as a critical player due to its focus on cutting-edge research initiatives aimed at discovering new therapeutic options. With growing investment in this sector, the collaboration between academia and industry is expected to yield innovative treatments, making it a vibrant area within the market.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for Parkinson’s Disease therapeutics, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a growing aging population, which drives demand for effective therapies. Regulatory support from agencies like the FDA further catalyzes market growth, facilitating quicker access to innovative treatments.

The United States is the primary contributor, hosting major pharmaceutical companies such as AbbVie, Amgen, and Eli Lilly. Canada also plays a vital role, with increasing investments in healthcare and research. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all striving to develop novel therapies that address unmet needs in Parkinson’s treatment.

### Europe : Robust Regulatory Framework

Europe is the second-largest market for Parkinson’s Disease therapeutics, holding around 30% of the global market share. The region's growth is propelled by a strong regulatory framework, with agencies like the European Medicines Agency (EMA) ensuring the safety and efficacy of new treatments. Additionally, increasing awareness and diagnosis rates contribute to rising demand for effective therapies across member states.

Leading countries include Germany, France, and the UK, which are home to key players such as Boehringer Ingelheim and Roche. The competitive landscape is marked by collaborations between pharmaceutical companies and research institutions, fostering innovation. The presence of a well-established healthcare system further supports the market, enabling better access to therapies for patients.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is witnessing rapid growth in the Parkinson’s Disease therapeutics market, accounting for approximately 20% of the global share. The region's growth is driven by increasing healthcare expenditure, rising awareness of neurological disorders, and a growing elderly population. Countries like Japan and China are leading the charge, supported by favorable government initiatives aimed at improving healthcare access and innovation in treatment options.

Japan stands out as a key player, with significant investments in research and development. The competitive landscape is evolving, with both multinational corporations and local firms striving to capture market share. The presence of major companies like Teva Pharmaceutical and Novartis enhances the region's therapeutic offerings, making it a focal point for future growth in Parkinson’s treatments.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa represent an emerging market for Parkinson’s Disease therapeutics, holding about 5% of the global market share. The region's growth is primarily driven by increasing healthcare investments and a rising prevalence of neurological disorders. Governments are focusing on enhancing healthcare infrastructure, which is expected to catalyze market expansion in the coming years.

Countries like South Africa and the UAE are leading the way, with growing awareness and initiatives aimed at improving patient care. The competitive landscape is still developing, with opportunities for both local and international players to introduce innovative therapies. The presence of key players is gradually increasing, paving the way for a more robust market in the future.

## Competitive Benchmarking

The Parkinson’s Disease Therapeutics Market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on patient-centric solutions. Key players such as AbbVie (US), Novartis (CH), and Eli Lilly and Company (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. AbbVie (US) focuses on expanding its portfolio through innovative drug development, while Novartis (CH) emphasizes strategic collaborations to enhance research capabilities. Eli Lilly and Company (US) is increasingly investing in digital health solutions, reflecting a broader trend towards integrating technology in therapeutic approaches. Collectively, these strategies not only bolster their competitive edge but also contribute to a rapidly evolving market landscape.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Parkinson’s Disease Therapeutics Market appears moderately fragmented, with a mix of established players and emerging biotech firms. The collective influence of these key players shapes the market structure, fostering an environment where innovation and strategic maneuvering are paramount.

In August 2025, AbbVie (US) announced a strategic partnership with a leading digital health company to develop a comprehensive management platform for Parkinson’s Disease. This initiative aims to integrate real-time patient data with therapeutic interventions, potentially revolutionizing patient care and adherence. Such a move underscores AbbVie’s commitment to leveraging technology to enhance treatment outcomes, positioning the company as a leader in patient-centric solutions.

In September 2025, Novartis (CH) launched a new clinical trial for a novel therapy targeting early-stage Parkinson’s Disease. This trial is part of a broader strategy to diversify its therapeutic offerings and address unmet medical needs. By focusing on early intervention, Novartis (CH) aims to establish itself as a pioneer in proactive treatment approaches, which could significantly alter the treatment paradigm in this space.

In July 2025, Eli Lilly and Company (US) unveiled a new AI-driven platform designed to streamline drug discovery processes for neurodegenerative diseases, including Parkinson’s. This technological advancement not only enhances the efficiency of research and development but also positions Eli Lilly (US) at the cutting edge of innovation in the therapeutics market. The integration of AI into drug development processes is likely to accelerate the pace of bringing new therapies to market, thereby enhancing competitive differentiation.

As of October 2025, the competitive trends in the Parkinson’s Disease Therapeutics Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex healthcare challenges. Looking ahead, the competitive landscape is expected to evolve, with a pronounced shift from price-based competition towards differentiation through innovation, technological advancements, and reliable supply chains. This transition may redefine how companies approach market entry and product development, emphasizing the importance of agility and responsiveness in a rapidly changing environment.

## Recent News & Developments

**In June 2019,** Biogen Inc. announced plans to acquire Nightstar Therapeutics, a gene therapy company focused on the development of treatments for inherited retinal diseases.

Biogen's acquisition of Nightstar also included its Parkinson's Disease gene therapy program, which is in preclinical development.

**In October 2019, **Adamas Pharmaceuticals launched a new product, Gocovri, for the treatment of dyskinesia in Parkinson's Disease patients who are on levodopa-based therapy.

Gocovri is the first and only FDA-approved medication for this indication.

**In February 2020, **Neurocrine Biosciences announced positive results from a phase 2 [clinical trial](../../../reports/clinical-trial-management-system-market-2054) of its Parkinson's Disease drug, NBI-827104.

The drug showed significant improvement in motor function in patients with Parkinson's Disease, and the company plans to move forward with phase 3 trials.

## Report Scope

| MARKET SIZE 2024 | 6.37(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.931(USD Billion) |
| MARKET SIZE 2035 | 16.11(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.8% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Market analysis in progress |
| Segments Covered | Market segmentation analysis in progress |
| Key Market Opportunities | Advancements in gene therapy and personalized medicine enhance treatment options in the Parkinson’s Disease Therapeutics Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competitive forces and regulatory changes in the Parkinson’s Disease therapeutics market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Parkinson’s Disease Therapeutics Market?**
A: As of 2024, the market valuation was 6.37 USD Billion.

**Q: What is the projected market size for the Parkinson’s Disease Therapeutics Market by 2035?**
A: The market is expected to reach a valuation of 16.11 USD Billion by 2035.

**Q: What is the expected CAGR for the Parkinson’s Disease Therapeutics Market from 2025 to 2035?**
A: The market is projected to grow at a CAGR of 8.8% during the forecast period 2025 - 2035.

**Q: Which treatment types are included in the Parkinson’s Disease Therapeutics Market?**
A: Key treatment types include Medication, Surgical Therapy, and Carbidopa/Levodopa Enteral Suspension.

**Q: What were the market values for Medication and Surgical Therapy in 2024?**
A: In 2024, Medication was valued at 3.8 USD Billion, while Surgical Therapy was valued at 1.5 USD Billion.

**Q: What is the projected market value for Medication by 2035?**
A: By 2035, the market value for Medication is expected to reach 9.5 USD Billion.

**Q: Who are the key players in the Parkinson’s Disease Therapeutics Market?**
A: Key players include AbbVie, Boehringer Ingelheim, Novartis, Roche, Teva Pharmaceutical Industries, Amgen, Eli Lilly and Company, Sanofi, and Pfizer.

**Q: What are the end-user segments in the Parkinson’s Disease Therapeutics Market?**
A: End-user segments include Hospitals & Clinics and Academic & Industrial Research.

**Q: What were the market values for Hospitals & Clinics and Academic & Industrial Research in 2024?**
A: In 2024, Hospitals & Clinics were valued at 3.81 USD Billion, while Academic & Industrial Research was valued at 2.56 USD Billion.

**Q: What is the expected market value for Hospitals & Clinics by 2035?**
A: The market value for Hospitals & Clinics is projected to reach 9.66 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/parkinsons-disease-therapeutics-market-1572*